published meta-analysis   sensitivity analysis   studies

potential COVID-19 treatments in COVID-19 mild to moderate - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsFACCT Trial, 2021 0.69 [0.28; 1.68] 0.69[0.28; 1.68]FACCT Trial, 202110%254NAnot evaluable deathsdetailed resultsDabbous HM, 2020 0.51 [0.02; 15.41] FACCT Trial, 2021 0.96 [0.44; 2.08] NCT04542694, 2020 1.00 [0.02; 50.90] Solaymani-Dodaran, 2021 1.22 [0.66; 2.26] Udwadia, 2020 0.50 [0.02; 15.03] 1.08[0.67; 1.72]Dabbous HM, 2020, FACCT Trial, 2021, NCT04542694, 2020, Solaymani-Dodaran, 2021, Udwadia, 202050%1,076moderatenot evaluable clinical improvementdetailed resultsAVIFAVIR, 2020 0.53 [0.13; 2.19] NCT04542694, 2020 2.10 [1.04; 4.24] Ruzhentsova T, 2020 1.63 [1.14; 2.34] Udwadia, 2020 1.75 [1.10; 2.79] 1.66[1.28; 2.15]AVIFAVIR, 2020, NCT04542694, 2020, Ruzhentsova T, 2020, Udwadia, 202040%578moderatenot evaluable clinical improvement (14-day)detailed resultsAVIFAVIR, 2020 0.53 [0.13; 2.19] Ruzhentsova T, 2020 1.28 [1.05; 1.56] 1.10[0.58; 2.11]AVIFAVIR, 2020, Ruzhentsova T, 2020231%228moderatenot evaluable clinical improvement (28-day)detailed resultsRuzhentsova T, 2020 1.11 [0.96; 1.29] Udwadia, 2020 1.75 [1.10; 2.79] 1.32[0.86; 2.03]Ruzhentsova T, 2020, Udwadia, 2020270%318moderatenot evaluable clinical improvement (7-day)detailed resultsNCT04542694, 2020 2.10 [1.04; 4.24] Ruzhentsova T, 2020 1.50 [1.02; 2.21] 1.62[1.15; 2.28]NCT04542694, 2020, Ruzhentsova T, 202020%368moderatenot evaluable clinical improvement (time to event analysis only)detailed resultsFACCT Trial, 2021 0.85 [0.62; 1.16] Ruzhentsova T, 2020 1.63 [1.14; 2.34] Shinkai, 2021 1.40 [0.91; 2.15] Solaymani-Dodaran, 2021 0.94 [0.75; 1.17] Udwadia, 2020 1.75 [1.10; 2.79] 1.22[0.91; 1.63]FACCT Trial, 2021, Ruzhentsova T, 2020, Shinkai, 2021, Solaymani-Dodaran, 2021, Udwadia, 2020572%1,108moderatenot evaluable hospital dischargedetailed resultsFACCT Trial, 2021 0.88 [0.64; 1.21] Udwadia, 2020 1.41 [0.97; 2.03] 1.10[0.69; 1.75]FACCT Trial, 2021, Udwadia, 2020272%404moderatenot evaluable mechanical ventilationdetailed resultsSolaymani-Dodaran, 2021 1.62 [0.85; 3.08] Udwadia, 2020 0.06 [0.01; 0.83] 0.41[0.02; 9.32]Solaymani-Dodaran, 2021, Udwadia, 2020283%387moderatenot evaluable mechanical ventilation (time to event analysis only)detailed resultsUdwadia, 2020 0.06 [0.01; 0.83] 0.06[0.01; 0.83]Udwadia, 202010%14NAnot evaluable viral clearance detailed resultsAVIFAVIR, 2020 3.89 [1.23; 12.29] Dabbous HM, 2020 1.33 [0.60; 2.93] NCT04542694, 2020 13.03 [2.96; 57.24] Ruzhentsova T, 2020 1.28 [0.92; 1.79] Udwadia, 2020 1.37 [0.94; 1.98] 1.83[1.12; 2.99]AVIFAVIR, 2020, Dabbous HM, 2020, NCT04542694, 2020, Ruzhentsova T, 2020, Udwadia, 2020567%677moderateserious viral clearance (time to event analysis only)detailed resultsRuzhentsova T, 2020 1.28 [0.92; 1.79] Udwadia, 2020 1.37 [0.94; 1.98] 1.32[1.03; 1.69]Ruzhentsova T, 2020, Udwadia, 202020%318moderatenot evaluable viral clearance by day 14detailed resultsAVIFAVIR, 2020 3.08 [0.62; 15.39] Ruzhentsova T, 2020 0.99 [0.93; 1.06] 1.30[0.50; 3.36]AVIFAVIR, 2020, Ruzhentsova T, 2020248%228moderatenot evaluable viral clearance by day 7detailed resultsAVIFAVIR, 2020 3.89 [1.23; 12.29] Dabbous HM, 2020 1.33 [0.60; 2.93] Ruzhentsova T, 2020 1.05 [0.92; 1.20] 1.44[0.78; 2.65]AVIFAVIR, 2020, Dabbous HM, 2020, Ruzhentsova T, 2020361%327moderatenot evaluable ICU admissiondetailed resultsFACCT Trial, 2021 1.42 [0.79; 2.55] Solaymani-Dodaran, 2021 1.23 [0.70; 2.18] 1.32[0.88; 1.99]FACCT Trial, 2021, Solaymani-Dodaran, 202120%627moderatenot evaluable serious adverse eventsdetailed resultsNCT04542694, 2020 6.15 [0.30; 124.49] Ruzhentsova T, 2020 2.06 [0.09; 46.40] Shinkai, 2021 2.80 [0.14; 56.95] Udwadia, 2020 1.03 [0.02; 52.48] 2.73[0.55; 13.60]NCT04542694, 2020, Ruzhentsova T, 2020, Shinkai, 2021, Udwadia, 202040%667moderatenot evaluable adverse eventsdetailed resultsNCT04542694, 2020 1.00 [0.54; 1.85] Ruzhentsova T, 2020 1.90 [0.96; 3.80] Shinkai, 2021 19.54 [7.77; 49.11] Udwadia, 2020 6.36 [2.43; 16.65] 3.78[1.07; 13.38]NCT04542694, 2020, Ruzhentsova T, 2020, Shinkai, 2021, Udwadia, 2020491%667moderatenot evaluable0.05.01.0relative treatment effectwww.metaEvidence.org2024-11-01 00:54 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 90 - treatments: 290,547,608,830,831,829,901,680,595,828,681,1209,833,629,689,543,617,625,859,511,960,546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525,843,827,1047,1048,819,545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814,649,650,589,651,968,1245,610,751,747,695,548,970,594,565,879,1257,571,626,697,572,1234,586,573,540,592,930,949,838,698,934,735,929,948,946,945,587,655,1146,531,933,613,919,725,678,921,621,959,748,1348,1256,924,1243,925,658,699,612,552,590,891,605,892,722,618,609,551,834,763,922,935,620,1317,1265,824,766,857,1291,1088,1331,1330,1329,1344,1328,1327,979,822,762,805,950,757,761,806,758,826,755,821,1288,1287,1286,760,1284,802,765,1285,759,823,804,1264,764,858,835,1262,1290,1316,1341,1342,1343,825,803,1244,523,885,734,1439 - roots T: 290